ReviewActa diabetologica2025
Microvascular disease and severe COVID-19 outcomes in UKBiobank participants with diabetes.
Review in Acta diabetologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between cardiovascular, psychotropic and anti-inflammatory/analgesic drug use and vascular dysfunction in individuals with long COVID. BioICOPER study.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
aimsEarly in the COVID-19 pandemic, evidence emerged suggesting that people with diabetic retinopathy (DR) or other microvascular diseases had greater risk of severe short-term outcomes. This study evaluated longer-term outcomes, providing more generalisable evidence.
methodsWe identified a cohort of UKBiobank participants with diabetes and retrieved their diagnostic codes for a variety of microvascular diseases, complications of diabetes and systemic comorbidities. We investigated relationships between diagnoses and the study outcome: admission to Critical Care or death from COVID-19, taking age, sex and diabetes duration into account. We tested relationships, adding baseline covariates and weighting diagnostic codes according to their recency prior to COVID-19 diagnosis.
resultsIn univariate analyses, DR (OR: 1·519, p = 0·016) and microvascular disease (OR: 2·001, p = 0·000) were associated with greater risk of the outcome. In multivariate analyses, as expected, respiratory disease was most strongly associated with the study outcome, microvascular disease second. Adjusting analyses by number of admissions (general health proxy) and weighted diagnostic coding (comorbidity severity at COVID-19 diagnosis indicator), did not improve predictive power of the model.
conclusionsThe presence of microvascular disease in routinely-collected healthcare data predicts risk of COVID-19 severe outcomes, independently of general health, in a cohort of people with diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.